Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844454 | 1.00 | SCN9A (0.52) | SCN9ACACNA1BTP53CNR2CTSL | |
| SCHEMBL20088469 | 0.96 | SCN9A (0.49) | SCN9ACACNA1BTP53CNR2CTSL | |
| SCHEMBL15844874 | 0.88 | SCN9A (0.42) | SCN9ATP53CNR2CTSLFPR2 | |
| SCHEMBL15844873 | 0.88 | SCN9A (0.42) | SCN9ATP53CNR2CTSLFPR2 | |
| SCHEMBL20088467 | 0.86 | SCN9A (0.40) | SCN9ATP53CNR2CTSLFPR2 | |
| SCHEMBL15843982 | 0.82 | SCN9A (0.58) | SCN9ACACNA1BALDH1A1 | |
| SCHEMBL15843983 | 0.82 | SCN9A (0.58) | SCN9ACACNA1BALDH1A1 | |
| SCHEMBL20088465 | 0.80 | SCN9A (0.54) | SCN9ACACNA1BMAPTALDH1A1 | |
| SCHEMBL15844420 | 0.80 | SCN9A (0.57) | SCN9ACACNA1B | |
| SCHEMBL15843891 | 0.80 | SCN9A (0.57) | SCN9ACACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | SCN9A 50/4885CACNA1B 17/4885TP53 4692/4885 |
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | SCN9A 52/4885CACNA1B 25/4885TP53 4747/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | SCN9A 52/4885CACNA1B 25/4885TP53 4747/4885 |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | SCN9A 50/4885CACNA1B 17/4885TP53 4692/4885 |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | SCN9A 39/4885CACNA1B 22/4885TP53 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.